In refractory leukemia, IV busulfan plus cyclophosphamide may be a valid alternative
the ONA take:
Intravenous busulfan plus cyclophosphamide may be a valid and efficient alternative to cyclophosphamide plus total body irradiation conditioning regimen for patients with refractory acute myeloid leukemia, according to a new study published online ahead of print in the The Lancet Haematology.
For the study, researchers analyzed data from 514 patients with refractory acute myeloid leukemia in active phase who had received intravenous busulfan plus cyclophosphamide and 338 patients who had received cyclophosphamide plus total body irradiation. All patients then received allogenic hematopoietic stem-cell transplantation from an HLA-identical sibling or an unrelated donor.
Results showed that 2-year overall survival and 2-year leukemia-free survival did not differ between the 2 groups. Researchers found that the main reasons for non-relapse mortality were graft-versus-host disease and infection.
The findings suggest that intravenous busulfan plus cyclophosphamide may be especially preferable for transplant centers that do not have access to radiation facilities.
Intravenous busulfan plus cyclophosphamide may be a valid and efficient alternative for patients with refractory acute myeloid leukemia.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
- Urine Drug Testing Policy Can Assist Opioid Treatment Decisions
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|